Antibodies Theranostics Market: Introduction
Antibodies theranostics means use of radiolabeled compounds for both diagnostics and therapeutic treatments. For example, monoclonal antibodies represent the increasing group of tumor cells. Molecular Imaging techniques such as SPECT and PET provide details regarding the whole-body distribution of radiolabeled mAbs and antibody-related therapeutics.
In 2016, antibodies in theranostics for the treatment of cancer were approved by the FDA. The antibodies used in theranostics are mainly composed of 20 mAbs, 1 BiTE, 2 ADCs, and 1 radio immunotherapy antibody.
There are several types of antibody theranostics tests such as immunohistochemistry test (IHC), enzyme linked immunosorbent assay (ELISA), and florocytometry.
Immunohistochemistry test is carried out for solid tumors. It is simple to perform and also budget friendly. The major disadvantage of this test is there is no information about target accessibility and it also requires invasive biopsies.
ELISA is performed to detect hematological cancer. In this test, there is a defined membranous expression. The major disadvantage is it does not target expression.
Antibodies Theranostics Market: Key Trends
- Theranostics in nuclear medicine is emerging. It means there is use of some radioactive compounds to image biological phenomena by means of expression of specific disease targets such as cell surface receptors or membrane transporters.
- Trastuzumab (Herceptin) is extensively used in theranostics. It is actually used for the detection of HER2 expression levels in the breast cancer. Around 30% of HER2 positive breast cancer responds to the trastuzumab therapy. SPECT and copper‐64 (64Cu)‐labelled or zirconium‐89 (89Zr)‐labelled trastuzumab PET are used to detect the HER2 positive lesions.
- The first therapeutic mAb approved by the FDA for the treatment of cancer was Rituximab. Rituximab is fixed against the cell surface marker CD20, which is further expressed on B‐lymphocytes and permitted for the treatment of non‐Hodgkin's lymphoma.
- Photo thermal therapy (PTT) is also one of the emerging fields to ablate the cancer cells. Mostly, gold coated with liposome is used as the PTT agent. It has both biocompatibility and excretory properties. PTT has advantages such as ease of therapeutic dose adjustment, high tumor selectivity, less invasiveness, and low likelihood of resistance.
- The evolution of types of cancers such as brain, kidney, liver, and breast creates several opportunities for players in the theranostics market.
- Major barriers to evolution can be high costs and experimental nature of the therapy. Additionally, healthcare costs and privation of awareness about post-cancer treatments are expected to remain challenges.
North America to Capture Major Share of Antibodies Theranostics Market
- North America is estimated to capture the highest share of the global market due to healthcare and pharmaceutical development. However, the patients present in the region are unaware about post cancer treatments. High cost of the treatment is also one of the challenges. Mayo clinics have discovered few techniques to treat the wounds caused by cancer. Companies such as Cardinal Health has invested a huge amount in the theranostics market.
- Asia Pacific is an emerging market due to rise in the healthcare expenditure and product innovation. Japan has promised to provide advanced therapies to cancer patients.
Key Players Operating in Global Antibodies Theranostics Market
The global antibodies theranostics market is fragmented due to the presence of international and local players. A large number of manufacturers hold major share in their respective regions. Demand for antibodies theranostics has increased in both emerging and developed markets owing to rise in awareness about technologically advanced products. Growth strategies adopted by leading players are likely to drive the global market.
Key players operating in the global antibodies theranostics market are:
- Thermo Fischer Scientific Inc.
- Beckman Coulter Inc.
- Hoffmann-la-Roche Ltd.
- Focus Diagnostics
- Illumina Inc.
- Agilent technologies Inc.
- Qiagen
- Abbott Laboratories
- Myriad Genetics Inc.
- Foundation Medicine Path Inc.
- AmeriPath Inc.
- Other Prominent Players
Global Antibodies Theranostics Market: Research Scope
Global Antibodies Theranostics Market, by Disease Type
- Oncology
- Cardiovascular Disease
- Neurological Disorder
- Immunological Disorder
- Others
Global Antibodies Theranostics Market, by Technology Type
- Polymerase Chain Reaction (PCR)
- Immunohistochemistry (IHC)
- In situ Hybridization
- Sequencing
- Others
Global Antibodies Theranostics Market, by End-user
- Hospitals & Clinics
- Diagnostic Laboratories
- Others
Global Antibodies Theranostics Market, by Region
- North America
- Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia & New Zealand
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC Countries
- South Africa
- Rest of Middle East & Africa
